Twist Bioscience Stock Price, News & Analysis

Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with Astellas Pharma Inc. to license a suite of VHH antibody libraries aimed at drug discovery and development. This partnership includes three agreements over five years. Twist will receive an upfront payment, annual maintenance fees, and milestone-related payments, potentially extending to royalties on product sales. The collaboration highlights Twist's capacity to support customer needs in pipeline development through its innovative antibody solutions. Twist's VHH libraries can target a wide range of proteins and are designed for high specificity and binding affinity, which improves therapeutic development for diseases like cancer and autoimmune disorders.

Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist T-cell Receptor (TCR) and chimeric antigen receptor (CAR) Libraries, designed to enhance the development of cell therapies. These libraries allow rapid creation of custom gene fragments, enabling researchers to fine-tune receptors for improved therapeutic outcomes. The libraries consist of up to 10,000 gene fragment combinations, facilitating high-throughput screening and exploration of variable binding regions.

CEO Emily M. Leproust stated that the new offerings will aid in addressing challenges like off-target toxicity. The libraries will be showcased at the AACR Annual Meeting 2023 in Orlando, Florida, with specific poster presentations scheduled throughout the event.

Twist Bioscience Corporation (NASDAQ: TWST) has announced its upcoming financial results for the fiscal 2023 second quarter, which ended on March 31, 2023. The results will be released before the market opens on May 5, 2023. A conference call is scheduled for 8:00 a.m. Eastern Time on the same day, where the company's financial performance and business updates will be discussed.

The press release will be available on the company's website in the Investor Relations section prior to the call. Twist Bioscience specializes in high-quality synthetic DNA manufacturing using a proprietary silicon-based platform, focusing on various applications across healthcare, agriculture, and genomics.

Twist Bioscience Corporation (NASDAQ: TWST) announced the launch of its integrated offering of antibody discovery services, combining its synthetic libraries, AI machine learning, and in vivo immunization through the acquisition of Abveris. This premium service aims to provide optimized, development-ready antibody candidates, enhancing throughput and speed for clients. The initiative is led by Tracey Mullen, newly appointed Senior VP of Biopharma. The offering will be showcased at the Festival of Biologics from March 20-22, 2023. The integrated approach facilitates improved discovery and optimization of diverse antibody formats, promoting success in preclinical development.

Twist Bioscience Corporation (NASDAQ: TWST) announced key presentations by CEO Emily M. Leproust and CFO Jim Thorburn at upcoming investor conferences. They will participate in the Cowen 43rd Annual Healthcare Conference on March 6-7, 2023, with a fireside chat on March 7 at 1:30 p.m. ET. The Barclays Global Healthcare Conference will occur on March 14, 2023, featuring a fireside chat at 2:05 p.m. ET. Both events will be webcasted live and available for replay for 30 days. Twist Bioscience specializes in synthetic DNA manufacturing, with applications across healthcare, agriculture, and more.

Twist Bioscience Corporation (NASDAQ: TWST) announced the discovery of alpaca-derived VHH antibodies via a novel in vivo screening method on the Beacon platform. The study, published in BioRxiv, showcases methodology that efficiently screens single B cells for specific heavy-chain-only antibodies, particularly targeting human prostate specific membrane antigen (PSMA). All VHH-Fc candidates demonstrated nanomolar affinity for PSMA. This approach allows for improved antibody optimization and potential therapeutic applications, leveraging Twist's advanced sequencing technologies.

Twist Bioscience (NASDAQ: TWST) announced early access to its enhanced Whole Genome Sequencing (eWGS) solution for non-human genomics at the AGBT 2023 meeting in Hollywood, Florida. This innovative solution allows researchers to obtain simultaneous low-pass whole genome data with deep coverage of specific regions, enhancing cost-effectiveness and high throughput. The eWGS workflow uses a modified 96-plex library preparation kit, facilitating the sequencing of 96 samples in a single tube, aimed at improving resolution and flexibility in agricultural genomics. Additionally, Twist will present three posters on next-generation sequencing and reference standards during the conference.

Twist Bioscience Corporation (NASDAQ: TWST) reported a strong start to fiscal 2023, with revenue of $54.2 million in the first quarter, reflecting a 29% increase from $42.0 million in the same quarter last year. Total orders rose to $64.7 million, a 30% increase year-over-year. Despite a net loss of $41.8 million, improvements were noted in expenses: Selling, General and Administrative costs dropped from $51.1 million to $42.3 million. The company shipped products to 2,060 customers and launched key partnerships in biopharma and DNA storage, showcasing robust growth and innovation in its core business areas.

Twist Bioscience Corporation (NASDAQ: TWST) announced the shipment of initial products from its new manufacturing facility in Wilsonville, Oregon, known as the Factory of the Future. This 110,000 square-foot facility is expected to double the company's manufacturing capacity, supporting substantial growth in production and revenue. CEO Emily M. Leproust expects the enhanced capacity will facilitate new product introductions, including 'fast genes' that promise quicker manufacturing turnaround times. Currently, the company offers turnaround times of 10 business days for clonal genes and 5 business days for gene fragments and oligo pools.